NSCLC Survival Rises with Checkpoint Blocker Add-On

(MedPage Today) -- Atezolizumab plus standard therapy also slows disease progression
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news

Related Links:

This study aimed to investigate whether the anti-tumor effect of gemcitabine (GEM) in non-small-cell lung cancer (NSCLC) treatment was affected by Danggui Buxue decoction (DBD), and explore the potential mechanisms. The combined use of GEM and DBD showed an enhanced tumor growth inhibition effect in a murine Lewis lung carcinoma (LLC) model. LC-MS/MS results showed that the pharmacokinetic behaviors of a GEM active metabolite, gemcitabine triphosphate (dFdCTP), were found to be altered remarkably in the peripheral blood mononuclear cells (PBMC) of DBD co-administration rats. In addition, after co-administration of DBD with...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
CONCLUSIONS: We have proved that the expression of miRNA-27a-3p, miRNA-31, miRNA-182, and miRNA-195 in patients with LC is different from the expression of these molecules in healthy people. The examination of these microRNAs in plasma could be used in non-invasive lung cancer diagnosis. PMID: 31115013 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: Our findings provide clues regarding the role of HJURP as a tumor promoter in NSCLC via the activation of the Wnt/β-catenin pathway, indicating HJURP may be a promising therapeutic target for NSCLC. PMID: 31115012 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: COX-2 might promote cisplatin resistance in NSCLC by promoting EMT through the AKT signaling pathway activation. PMID: 31115011 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: We demonstrated that linc00261 was lowly expressed in NSCLC tissues and cells. It inhibited cell proliferation and metastasis by downregulating Snail expression via EMT. This might provide a novel sight for the biological treatment for NSCLC. PMID: 31115010 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
ConclusionPatients with stage III NSCLC and a large MTV in whom definitive RCT had a particularly good survival in the ESPATUE trial. Treatment individualization according to MTV is not supported by this study. The ESPATUE and ACRIN trials differed by the use of cisplatin-containing induction chemotherapy and an intensified radiotherapy regimen that were particularly effective in patients with large MTV disease.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Telomere genetics has recently been emerged as an important field in molecular oncology. Various genome-wide association studies in different population groups have revealed that polymorphisms in Telomere main...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Fatty acid synthase (FASN) is overexpressed in most human carcinomas, including non-small cell lung cancer (NSCLC), and contributes to poor prognosis. An increasing number of studies have highlighted the poten...
Source: Lipids in Health and Disease - Category: Lipidology Authors: Tags: Research Source Type: research
Conclusion: In view of the poor specificity, the current study calls for reconsideration of the universal recommendation of dedicated brain imaging (in addition to PET/CT scan) among NSCLC patients beyond stage I. PMID: 31116030 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
SummaryEntrectinib is a pan-tyrosine-kinase inhibitor that targets oncogenic rearrangements inNTRK,ROS1 andALK. The combined results of two clinical trials demonstrated the efficacy of entrectinib inROS1-rearranged NSCLC. Because the development of drug resistance is inevitable, it would be helpful to determine the mechanisms of entrectinib resistance in aROS1-rearranged tumor model so that future therapeutic strategies can be developed. Here, we characterized the molecular basis of resistance in entrectinib-resistantROS1-rearranged HCC78 cells (HCC78ER cells). These cells were analyzed by next-generation sequencing and ge...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Non-Small Cell Lung Cancer | Primary Care